
|Articles|January 1, 2004
FDA approves first accommodative IOL
Cataract surgeons who participated in the premarketing clinical trials for the model AT-45 accommodative IOL (Crystalens, eyeonics inc. [formerly C&C Vision]) are heralding that technology as an important advance. The lens affords patients clear uncorrected vision at near, intermediate, and distance. FDA approval for marketing of the lens was granted in November.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Eydenzelt, Celltrion’s biosimilar referencing Eylea, approved in Canada
4
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
5

















































.png)


